New York, March 04, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Hematology Drugs Global Market Report 2022” – https://www.reportlinker.com/p06241974/?utm_source=GNW
The global hematology drugs market is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $49.18 billion in 2026 at a CAGR of 8.0%.
The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases.This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma.
It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots.
The main drug types of hermatology drugs are blood products, anemia and other blood disorder drugs.Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood…
